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Background: LDL-cholesterol (LDL-C) has traditionally been used to gauge cardiovascular risk. However, LDL-C provides limited predictive 
information on fatal CVD complications in patients with established coronary artery disease (CAD). Thus we performed lipidomic analyses in two 
independent CVD studies to identify biomarkers for unstable CAD.
methods: Samples from two nested case-control studies (LURIC n=445 and Corogene n=434) were analyzed with direct infusion coupled tandem 
mass spectrometry and liquid chromatography tandem mass spectrometry (LC-MS/MS) approaches to identify characteristic plasma lipidome 
changes that associate with CVD death in CAD patients.
results: In both studies distinct ceramide species and particularly their ratios appeared as potential markers of unstable CAD. Following ceramide 
ratios were highly significant predictors of CVD death in both studies: Cer(d18:1/16:0)/Cer(d18:1/24:0) +27.3%, p = 5.4E-10 in LURIC and +26%, 
p = 3.7E-13 in Corogene; Cer(d18:1/24:1)/Cer(d18:1/24:0) +21.2%, p = 2.1E-11 in LURIC and +24%, p = 2.7E-15 in Corogene. Furthermore, the 
respective fourth quartile odds ratios for CVD death in the Corogene study were 12.3 (5.5.27-3) and 10.6 (5.1-22.0).
conclusion: The data obtained from two independent studies show that distinct ceramide species identify high risk CAD patients. These new 
markers are superior to currently used clinical lipid markers for prediction of CAD risk. Importantly these markers are actionable as plasma ceramide 
levels can be lowered with statins and/or PCSK9 inhibition and their concentrations can be monitored to follow treatment efficacy.
